## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)																
1. Name and Address of Reporting Person* Mann Brenda				2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director X Officer (give title below)  VP of Research & Development						
(Last) (First) (Middle) C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLEY OAKS ROAD, SUITE 108				3. Date of Earliest Transaction (Month/Day/Year) 10/04/2021							y/Year)		VP of Re	search & De	evelopment			
(Street) WALTHAM, MA 02452				4. If Amendment, Date Original Filed(Month/Day/Year)							h/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City	(City) (State) (Zin)					Tal	Table I - Non-Derivative Securities Acqu						lired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, any (Month/Day/Yea			(Instr. 8)		ction	4. Securities Acquired (A) or Disposed of (D (Instr. 3, 4 and 5)		Beneficia	nt of Securiti Ily Owned F Transaction and 4)	ollowing	6. Ownership Form: Direct (D)	of Indire Benefici	7. Nature of Indirect Beneficial Ownership	
							Co	ode	V	Amour	(A) or (D)	Price				or Indirec (I) (Instr. 4)	(Instr. 4	.)
Common	Stock		10/04/2021				F	(1)		62		\$ 2.01	15,198			D		
Reminder:	Report on a s	separate line fo		Deriva	ative Sec	uritie	es Ac	quire	Pers cont the f	ons whained i	no respo in this for splays a of, or Ber	rm ar curre reficia	e not requently valid	ction of inf uired to res OMB conf	spond unle	ess	C 1474 (9-	-02)
1 75'41 . C	I <sub>2</sub>	3. Transactio						ts, op			tible secu			0 D : C	0.31 1	C 10	1,, ,	NT /
Security	Conversion or Exercise Price of Derivative Security	Date	Execution Da	te, if	Code	ion N	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		and Expiration Date (Month/Day/Year) US		Am Un Sec	Fitle and count of derlying curities str. 3 and	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owner Form of Deriva Securi Direct or Indi	of Bene Own (Inst (D) rect	of Indirect Beneficia Ownershi (Instr. 4)	
					Code	V	(A)	(D)	Date Exer	cisable	Expiratio Date	n Titl	Amount or Number of Shares					

### **Reporting Owners**

Reporting Owner Name / Address		Relationships						
		10% Owner	Officer	Other				
Mann Brenda C/O EYEGATE PHARMACEUTICALS, INC. 271 WAVERLEY OAKS ROAD, SUITE 108 WALTHAM, MA 02452			VP of Research & Development					

### **Signatures**

/s/ Sarah Romano, Attorney-in-Fact*	10/05/2021
Signature of Reporting Person	Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Sale of shares to cover taxes due on restricted stock that vested on 10/01/2021.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.